Biotech Values

[Titan V]

Women’s health biotech KaNDy dickering with Allergan about a $400M buyout deal
https://endpts.com/womens-health-biotech-kandy-dickering-with-allergan-about-a-400m-buyout-deal-report/

Bloomberg is reporting this morning that Allergan $AGN is in late-stage talks to buy out KaNDy Therapeutics in a deal that could value the company at up to $400 million.

Details are few and far between, but the company has a potential hormone replacement therapy called NT-814 that would fit the profile for Allergan’s BD team.

NeRRe Therapeutics, which spun out of GSK taking some unwanted programs in neurosciences, split off the women’s health biotech a few months ago.

KaNDy took a neurokinin-1,3 receptor antagonist — with potential as a hormone replacement therapy — with plans to take it into a Phase IIb study for postmenopausal vasomotor symptoms.

That would give Allergan some human data to look at as it beefs up that section of the pipeline, if a deal is completed.

KaNDy Therapeutics is led by managing director Mary Kerr and chaired by Iain Dukes, a venture partner at OrbiMed Advisors. The company is based at the Stevenage Bioscience Catalyst in the UK.